Zetia

CETP inhibitor class finally dies as Merck abandons anacetrapib

Some have argued that the company should file given its big investment in the project and established commercial infrastructure, which succeeded in turning another cholesterol-lowering drug with lacklustre data - Zetia

Merck & Co's anacetrapib data fails to generate much excitement

selling Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin) in this therapeutic area despite a small effect on cardiovascular outcomes.

First round to Amgen in PCSK9 patent battle with Sanofi

For example, some payers are insisting that patients on statins try adding Merck &Co's selective cholesterol-absorption inhibitor Zetia (ezetimibe) before moving on to a PCSK9 inhibitor.

NICE backs Repatha but rejects cholesterol rival Praluent

Specifically, the UK watchdog said it was concerned that unlike Repatha Praluent has not been compared to the existing combination therapy of a statin plus MSD's Zetia (ezetimibe) in clinical

FDA panel rejects cardiovascular outcomes claim for Vytorin

It found a modest benefit with the addition of CETP inhibitor ezetimibe (Merck's Zetia) to the statin; 32.7% of the combination group suffered a major cardiovascular event over a ... Regardless of the outcome of the FDA's deliberations, Merck will face

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 [ Next 5 results ]